ArticleBMC cancer2026
Patients with tumor deposits benefit equally from adjuvant therapy compared to other stage III colon cancer groups: two retrospective population-based studies.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor deposits (TD) are independent poor prognostic indicators of an increased risk of distant metastasis. In TNM classification, they are included in the N1c subcategory in the absence of lymph node metastasis (LNM). However, there is still limited knowledge regarding the relative effects of systemic treatment in colon cancer (CC) patients with TD. MATERIAL-
methodWe conducted a retrospective population-based analysis of over 50,000 stage III CC patients from the Dutch and SEER cohorts. Patients were subdivided into groups based on the presence of TD, LNM, or both, and whether or not they received systemic treatment. Relative treatment effects were assessed by calculating the hazard ratios (HR) for 5-year overall survival (OS) in each group.
resultsIn the Dutch cohort of 13,704 patients, systemic treatment resulted in a constant better 5-year OS with HR 3.5 (%95 CI 3.2–3.7) for the LNM group, 4.6 (95% CI 3.2–6.8) for the TD group, and 3.5 (95% CI 3.2–4.0) for the LNM + TD group (all p < .001). A similar effect of treatment was seen in the SEER cohort of 43,148 patients, where HR for the LNM, TD, and LNM + TD groups were 3.0 (95% CI 2.9–3.1), 3.2 (95% CI 2.8–3.7), and 3.0 (95% CI 2.8–3.1), respectively (all p < .001).
conclusionsRelative effect of treatment was consistent across all three groups in both cohorts which suggest patients with TD benefit from treatment similarly to other groups. Our results highlight the importance of classifying patients with TD as stage III, even in the absence of LNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.